Cover art for Larimar Therapeutics Q3 2026 Results

Larimar Therapeutics Q3 2026 Results

Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.

3 cards · 40s · tap to begin

From · · · 40s

Larimar Therapeutics Q3 2026 Results

Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.

In brief

Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.

Q3 2026 Financial Results

Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026.

Per-Share Loss Narrowed

The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.

Analyst Support

Analyst Support

Wall Street maintains a broadly positive view with 8 buy, 1 hold, 0 sell consensus.

In short

Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025.

Read the original on Alphastreet - Earnings Decoded. Market Intelligence Delivered

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on earnings and related topics.